NC study tracks COVID-19 antibodies in healthy adults for a year
NCT ID NCT04490174
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 643 healthy adults in central North Carolina for one year to see how many developed antibodies to the COVID-19 virus. Participants had blood drawn five times and completed weekly symptom surveys. The goal was to better understand exposure rates and immune response to inform public health strategies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
643 people
The number who actually took part.
- Started
-
Aug 2020
- Finished
-
Dec 2023
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy adults \>18 years age without a current active COVID-19 infection or current symptoms consistent with COVID-19 within Central North Carolina.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Male and females 2. greater than or equal to 18 years of age 3. Able to read and speak English 4. Ability to provide informed consent 5. Able to travel to study visits at the NIEHS CRU for required study visits 6. Stated willingness to comply with all study procedures and availability for the duration of the study EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Current symptoms consistent with COVID-19 infection at the point of Antibody Visit 1 2. Inability to provide a blood sample 3. Current pregnancy or lactation, by participant verbal confirmation. 4. Any condition that, in the investigator's opinion, places the participant at undue risk for complications associated with required study procedures. 5. Not willing to have blood samples stored for future research Participants who have Limited English Proficiency will be excluded from the study because the informed consent form is only available in English. The study documents (Demographic and Health Assessment Questionnaire, and Weekly Symptom Questionnaire) and FDA Fact Sheets for Tests with Emergency Use Authorization are only available in English. Decisionally impaired adults and prisoners will be excluded due to the inability to complete necessary study procedures. Adults who become prisoners or decisionally impaired while on study will be withdrawn. Pregnant women are excluded due to the need to have participants venture out during the COVID-19 pandemic. Women who become pregnant during the study will be withdrawn. Children will be excluded from enrolling in this study as immunity in children is different than adults and we are focusing on adult immunity and in this trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID -19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NIEHS Clinical Research Unit (CRU)
Research Triangle Park, North Carolina, 27709, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can lung ultrasound reveal COVID-19's signature in the lungs?
- When the immune system Can't fight back: tracking three respiratory viruses
- The household maze: how does COVID-19 move between family members?
- Can an oral drug stop COVID-19 from turning deadly?
- Can COVID-19 rapid tests slip into HIV and TB clinics without disrupting care?